[ACAD] ACADIA Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 29.75 Change: 2.08 (7.52%)
Ext. hours: 29.65 Change: -0.1 (-0.34%)

chart ACAD

Refresh chart

Strongest Trends Summary For ACAD

ACAD is in the long-term up 1105% in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -85.71% Sales Growth - Q/Q-91.67% P/E-10.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.09% ROE-40.35% ROI
Current Ratio18.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-123217% Net Profit Margin-122364% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.44 M Cash From Investing Activities38.47 M Cash From Operating Activities-25.35 M Gross Profit
Net Profit-40.38 M Operating Profit-40.55 M Total Assets301.96 M Total Current Assets299.9 M
Total Current Liabilities16.65 M Total Debt Total Liabilities16.87 M Total Revenue
Technical Data
High 52 week39.14 Low 52 week15.12 Last close17.87 Last change1.53%
RSI52.92 Average true range0.66 Beta1.75 Volume3.38 M
Simple moving average 20 days0.08% Simple moving average 50 days-2.47% Simple moving average 200 days-35.73%
Performance Data
Performance Week2.47% Performance Month-2.14% Performance Quart-30.98% Performance Half-40.61%
Performance Year-34.78% Performance Year-to-date-40.65% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.94% Volatility yearly30.98% Relative Volume1230.89% Average Volume2.95 M
New High New Low

News

2019-03-13 13:18:04 | Is ACADIA Pharmaceuticals Inc.’s NASDAQ:ACAD Liquidity Good Enough?

2019-03-05 14:36:00 | Why Acadia Pharmaceuticals Stock Perked Up in February

2019-03-04 09:00:00 | ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019

2019-02-27 20:21:28 | Edited Transcript of ACAD earnings conference call or presentation 26-Feb-19 10:00pm GMT

2019-02-27 09:30:00 | 3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

2019-02-27 01:05:40 | Acadia Pharmaceuticals Inc ACAD Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-26 13:28:31 | Big Pharma faces the Senate in drug price hearings

2019-02-21 09:00:00 | ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

2019-02-15 16:08:09 | What's in the Cards for Bausch Health BHC Q4 Earnings?

2019-02-14 12:58:05 | 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings

2019-02-13 08:15:00 | New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

2019-02-12 09:00:00 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019

2019-02-11 16:51:09 | Zoetis ZTS to Report Q4 Earnings: What's in the Cards?

2019-02-11 15:58:08 | Is a Disappointment in Store for Incyte INCY Q4 Earnings?

2019-02-08 16:56:09 | Tilray TLRY to Report Q4 Earnings: What's in the Cards?

2019-02-08 08:07:05 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-02-07 16:31:09 | Exelixis EXEL to Report Q4 Earnings: What's in Store?

2019-01-31 19:18:12 | Will Gilead GILD Q4 Earnings Disappoint on Weak HCV Sales?

2019-01-30 10:02:03 | Is a Beat in Store for Vertex VRTX This Earnings Season?

2019-01-29 08:03:35 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-01-28 09:37:02 | MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

2019-01-28 08:00:00 | Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals

2019-01-24 06:46:11 | Will ACADIA Pharmaceuticals Continue to Surge Higher?

2019-01-21 11:48:38 | Does ACADIA Pharmaceuticals Inc.’s NASDAQ:ACAD CEO Pay Compare Well With Peers?

2019-01-17 10:18:03 | Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

2019-01-17 08:02:28 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-01-11 18:08:15 | Glancy Prongay & Murray LLP Announces Investigation On Behalf Of ACADIA Pharmaceuticals Inc. Investors ACAD

2019-01-09 08:02:08 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2019-01-08 15:38:00 | Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December

2018-12-27 13:55:02 | Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

2018-12-27 12:25:02 | Spectrum Pharmaceuticals: Financial Overview in December

2018-12-20 09:00:00 | ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

2018-12-16 23:37:54 | Is ACADIA Pharmaceuticals Inc. ACAD A Good Stock To Buy?

2018-12-13 10:46:04 | Why ACADIA Pharmaceuticals Inc. NASDAQ:ACAD Could Be Your Next Investment

2018-12-04 08:02:47 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2018-12-03 08:10:00 | Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-30 16:05:00 | ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2018-11-29 10:23:32 | Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday

2018-11-28 11:01:00 | Here's Why Acadia Pharmaceuticals Is Soaring

2018-11-28 07:00:00 | Today’s Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals

2018-11-27 21:20:00 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock

2018-11-27 15:22:00 | Why Acadia Pharmaceuticals Is Plummeting

2018-11-27 08:03:12 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2018-11-27 07:32:26 | The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

2018-11-27 06:55:00 | Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals

2018-11-26 16:08:00 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

2018-11-26 11:33:36 | A Look at Amarin Corporation’s Stock Performance Year-to-Date

2018-11-24 08:07:38 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

2018-11-16 08:07:45 | See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.